Zekai Tahir Burak Maternity Teaching Hospital, Division of Neonatology
Ankara, 06110, Turkey (Türkiye)
NCT Number: NCT01536158
The purpose of this study is to determine whether oral paracetamol or ibuprofen has a better or same efficacy and tolerance in closure of patent ductus arteriosus in preterm infants.
Looking for future studies?
Notify Me2 day–10 day
All sexes
Interventional
Phase 4
Ankara, 06110, Turkey (Türkiye)
To determine whether oral paracetamol or ibuprofen has a better or same efficacy and tolerance in closure of patent ductus arteriosus in preterm infants.
Eighty preterm infants with patent ductus arteriosus will be enrolled in this prospective-randomized study. Patients will receive oral ibuprofen at an initial dose of 10 mg/kg, followed by 5 mg/kg at 24 and 48 h or oral paracetamol 15 mg/kg per dose every 6 hours.
One of the following echocardiographic criteria of a duct size >1.5 mm, a left atrium-to-aorta ratio >1.5, left-to-right shunting of blood, end diastolic reversal of blood flow in the aorta, or poor cardiac function in addition signs of patent ductus arteriosis determined the need of treatment.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Patients will receive oral paracetamol 15 mg/kg per dose every 6 hours for 3 days.
Other names: Calpol
Patients will receive oral ibuprofen at an initial dose of 10 mg/kg, followed by 5 mg/kg at 24 and 48 h.
Other names: Pedifen
Time frame: Until discharge
To compare the closure rate of patent ductus arteriosus after oral paracetamol or oral ibuprofen treatment
Time frame: corrected 36 weeks or until discharge
Long term effects such as ROP, BPD,IVH, duration of respiratory support and hospitalization are going to be evaluated.
Zekai Tahir Burak Women's Health Research and Education Hospital
Other
Oral Paracetamol Versus Oral Ibuprofen Treatment
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07533721
Bronchopulmonary Dysplasia, Cardiovascular Abnormalities
Shenyang, Liaoning, China
View Trial DetailsNCT05639309
Cardiovascular Abnormalities, Cardiovascular Diseases
Seoul, Seocho-Gu, South Korea
View Trial DetailsNCT02884219
Cardiovascular Abnormalities, Cardiovascular Diseases
Antwerp, Belgium
View Trial DetailsNCT03551600
Cardiovascular Abnormalities, Cardiovascular Diseases
Murray, Utah, United States
View Trial Details